Oncology Imaging
This article was originally published in The Gray Sheet
Executive Summary
Interagency Council on Biomedical Imaging in Oncology, including representatives from FDA, the Health Care Financing Administration, and the National Institutes of Health's National Cancer Institute, will hold its next meeting Nov. 20, NIH says. The multi-agency group, which had its inaugural meeting in July as a sounding board for advice to investigators and manufacturers seeking to market new imaging technology, is accepting requests to be heard until Oct. 9. The council had reviewed 18 requests from large and small firms, as well as from members of academia. The meeting is closed to the public
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.